Amana Proudfoot

Dr. Amana Proudfoot


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2017 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
APAmana Proudfoot
Amana Proudfoot
ZJZoë Johnson
Zoë Johnson
PBPauline Bonvin
Pauline Bonvin
THTracy Handel
Tracy Handel
Chemokines have two types of interactions that function cooperatively to control cell migration. Chemokine receptors on migrating cells integrate signals initiated upon chemokine binding to promote cell movement. Interactions with glycosaminoglycans (GAGs) localize chemokines on and near cell surfaces and the extracellular matrix to provide direction to the cell movement. The matrix of interacting chemokine–receptor partners has been known for some time, precise signaling and trafficking properties of many chemokine–receptor pairs have been characterized, and recent structural information has revealed atomic level detail on chemokine–receptor recognition and activation. However, precise knowledge of the interactions of chemokines with GAGs has lagged far behind such that a single paradigm of GAG presentation on surfaces is generally applied to all chemokines. This review summarizes accumulating evidence which suggests that there is a great deal of diversity and specificity in these interactions, that GAG interactions help fine-tune the function of chemokines, and that GAGs have other roles in chemokine biology beyond localization and surface presentation. This suggests that chemokine–GAG interactions add complexity to the already complex functions of the receptors and ligands.

1 June 2019 in Trends in Immunology
Verified
Journal Article
Open access
GGGerard J. Graham
Gerard J. Graham
THTracy Handel
Tracy Handel
APAmana Proudfoot
Amana Proudfoot
Recruitment of immune cells from the vasculature relies on the presentation of glycosaminoglycan-bound chemokines on the luminal side of vascular endothelial cells. However, the current model of chemokine-glycosaminoglycan interactions, and its implications for receptor interactions, remains poorly developed. We propose a refined 'Chemokine Cloud' model, arguing that chemokines are not presented to leukocytes bound to glycosaminoglycans, but rather, in solution while sequestered within the hydrated glycocalyx. We posit that glycosaminoglycans provide an immobilized chemokine depot maintaining a 'cloud' of 'solution-phase' chemokines within the glycocalyx, and that it is this soluble form of any given chemokine that interacts with leukocyte-bound receptors. Our proposition clarifies certain anomalies associated with the current model of chemokine-glycosaminoglycan interactions, with implications for the design of blockers of chemokine function.

1 August 2015 in Cytokine
Verified
Journal Article
Closed access
APAmana Proudfoot
Amana Proudfoot
PBPauline Bonvin
Pauline Bonvin
CPChristine A. Power
Christine A. Power

1 February 2020 in Trends in Biochemical Sciences
Verified
Journal Article
Open access
RBRam Bhusal
Ram Bhusal
JEJames R.O. Eaton
James R.O. Eaton
SCSayeeda T. Chowdhury
Sayeeda T. Chowdhury
CPChristine A. Power
Christine A. Power
APAmana Proudfoot
Amana Proudfoot
SBShoumo Bhattacharya
Shoumo Bhattacharya
Ticks are hematophagous arachnids that parasitize mammals and other hosts, feeding on their blood. Ticks secrete numerous salivary factors that enhance host blood flow or suppress the host inflammatory response. The recruitment of leukocytes, a hallmark of inflammation, is regulated by chemokines, which activate chemokine receptors on the leukocytes. Ticks target this process by secreting glycoproteins called Evasins, which bind to chemokines and prevent leukocyte recruitment. This review describes the recent discovery of numerous Evasins produced by ticks, their classification into two structural and functional classes, and the efficacy of Evasins in animal models of inflammatory diseases. The review also proposes a standard nomenclature system for Evasins and discusses the potential of repurposing or engineering Evasins as therapeutic anti-inflammatory agents.

2 August 2013 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
MDMaud Déruaz
Maud Déruaz
PBPauline Bonvin
Pauline Bonvin
ISIndia C. Severin
India C. Severin
ZJZoë Johnson
Zoë Johnson
SKSonja Krohn
Sonja Krohn
APAmana Proudfoot
Amana Proudfoot
Rhipicephalus sanguineus, the common brown dog tick, produces several chemokine‐binding proteins which are secreted into the host in its saliva to modulate the host response during feeding. Two of these demonstrate very restricted selectivity profiles. Here, we describe the characterization of the third, which we named Evasin‐4. Evasin‐4 was difficult to produce recombinantly using its native signal peptide in HEK cells, but expressed very well using the urokinase‐type plasminogen activator signal peptide. Using SPR, Evasin‐4 was shown to bind most CC chemokines. Investigation of the neutralization properties by inhibition of chemokine‐induced chemotaxis showed that binding and neutralization did not correlate in all cases. Two major anomalies were observed: no binding was observed to CCL2 and CCL13, yet Evasin‐4 was able to inhibit chemotaxis induced by these chemokines. Conversely, binding to CCL25 was observed, but Evasin‐4 did not inhibit CCL25‐induced chemotaxis. Size‐exclusion chromatography confirmed that Evasin‐4 forms a complex with CCL2 and CCL18. In accordance with the standard properties of unmodified small proteins, Evasin‐4 was rapidly cleared following in vivo administration. To enhance the in vivo half‐life and optimize its potential as a therapeutic agent, Fc fusions of Evasin‐4 were created. Both the N‐ and C‐terminal fusions were shown to retain binding activity, with the C‐terminal fusion showing a modest reduction in potency.

26 May 2015 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
APAmana Proudfoot
Amana Proudfoot
Chemokines and Glycosaminoglycans